Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Clinical and Translational Medicine
Published in:

Open Access 01-12-2017 | Research

Styrene maleic acid encapsulated raloxifene micelles for management of inflammatory bowel disease

Authors: Khaled Greish, Safa Taha, Anfal Jasim, Sara Abd Elghany, Ameera Sultan, Ali AlKhateeb, Manal Othman, Fang Jun, Sebastien Taurin, Moiz Bakhiet

Published in: Clinical and Translational Medicine | Issue 1/2017

Login to get access

Abstract

Background

Inflammatory bowel disease (IBD) comprises a group of disorders that manifest through chronic inflammation of the colon and small intestine. Although the exact cause of IBD is still unclear, dysfunctional immunoregulation involving overproduction of inflammatory cytokines such as TNF-α, and IL-6 have been implicated in pathogenesis. Current therapy relies on immunosuppression, cytotoxic drugs, and monoclonal antibodies against TNF-α. These classes of drugs have severe side-effects, especially when used for long duration. Our previous work with raloxifene, a selective estrogen receptor modulator, has shown that the drug, and to a greater extent its micellar formulation, has a significant suppressive effect on NF-κB, an essential immune-regulator. This finding directed the current work towards testing the anti-inflammatory and immunomodulatory effects of raloxifene using cell lines, as well as testing the potential use of the styrene maleic acid (SMA) micelles loaded with raloxifene (SMA-Ral) against dextran sulfate sodium (DSS) induced colitis in an in vivo model of IBD.

Results

Treatment of MCF-7 cells with TNF-α was shown to protect the cells from the cytotoxic effect of raloxifene (42 vs. 10% cell death, with TNF-α. Treating CaCo-2 cells with both free and SMA-Ral improved cell survival after exposure to 2% DDS with significantly higher protection with SMA-Ral. Treatment of U-937 with SMA-Ral and free-Ral resulted in down-regulation of TNF-α, IL-1β, IL-6, and MIP1α, with greater inhibition of the SMA-Ral, compared to free Ral. Balb/c mice treated with raloxifene and SMA-Ral showed weight gain at 14 days, compared to the control group (122, and 115% respectively). Treatment with raloxifene prevented DSS-induced diarrhea in 6/6 of free raloxifene treated mice and in 5/6 mice treated with SMA-Ral. Control group of DSS-treated mice showed average colon length of 7.4 cm compared to 13 cm in the control group. The average colon length was 12.3 and 11.5 cm for raloxifene and SMA-Ral treated groups, respectively. Furthermore, inflammatory cytokines such as IL-6 and TNF-α were reduced in serum of animals treated with free-Ral and SMA-Ral.

Conclusions

Raloxifene and its micellar formulation warrants further studies to understand their effect on the treatment of colitis.
Appendix
Available only for authorised users
Literature
1.
Dignass A et al (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohn’s Colitis 6(10):991–1030CrossRef
2.
Cosnes J et al (2011) Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140(6):1785–1794CrossRefPubMed
3.
Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126(6):1504–1517CrossRefPubMed
4.
5.
Molodecky NA et al (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142(1):46–54CrossRefPubMed
6.
7.
Neurath MF et al (1996) Local administration of antisense phosphorothiate olignucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 2(9):998–1004CrossRefPubMed
8.
Rogler G et al (1998) Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115(2):357–369CrossRefPubMed
9.
Ito H et al (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 126(4):989–996CrossRefPubMed
10.
Phiel KL et al (2005) Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett 97(1):107–113CrossRefPubMed
11.
Verdú EF et al (2002) Modulatory effects of estrogen in two murine models of experimental colitis. Am J Physiol Gastrointest Liver Physiol 283(1):G27–G36CrossRefPubMed
12.
Sporn MB et al (2004) Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin Ther 26(6):830–840CrossRefPubMed
13.
Taurin S et al (2014) A novel role for raloxifene nanomicelles in management of castrate resistant prostate cancer. Biomed Res Int 2014:14CrossRef
14.
Archibald M et al (2016) A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer. Int J Nanomed 11:179–201
15.
Taurin S et al (2013) Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression. Int J Oncol 43:785–792PubMed
16.
Sartor RB, Hoentjen F (2005) Proinflammatory cytokines and signaling pathways in intestinal innate immune cells. In: Mucosal immunology, two-volume set. Elsevier Inc., pp 681–701
17.
Lim H-K et al (2012) Free radical metabolism of raloxifene in human liver microsomes. Xenobiotica 42(8):737–747CrossRefPubMed
18.
Greish K et al (2005) Copoly(styrene-maleic acid)–pirarubicin micelles: high tumor-targeting efficiency with little toxicity1. Bioconjug Chem 16(1):230–236CrossRefPubMed
19.
Greish K et al (2004) SMA–doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. J Control Release 97(2):219–230CrossRefPubMed
20.
Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112–1116CrossRefPubMed
21.
Cornish JA et al (2008) The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 103(9):2394–2400CrossRefPubMed
22.
Greish K et al (2003) Macromolecular therapeutics. Clin Pharmacokinet 42(13):1089–1105CrossRef
23.
Parayath NN et al (2015) Styrene maleic acid micelles as a nanocarrier system for oral anticancer drug delivery—dual uptake through enterocytes and M-cells. Int J Nanomed 10(1):4653–4667
24.
25.
26.
Li CKF et al (1998) Production of proinflammatory cytokines and inflammatory mediators in human intestinal epithelial cells after invasion by Trichinella spiralis. Infect Immun 66(5):2200–2206PubMedPubMedCentral
27.
Chassaing B et al (2014) Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol 104:25PubMed
28.
Laroui H et al (2012) Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon. PLoS ONE 7(3):e32084CrossRefPubMedPubMedCentral
29.
30.
Atreya R et al (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 6(5):583–588CrossRefPubMed
31.
Yamamoto M et al (2000) IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 164(9):4878CrossRefPubMed
32.
Scheinfeld N (2004) A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat 15(5):280–294CrossRef
Metadata
Title
Styrene maleic acid encapsulated raloxifene micelles for management of inflammatory bowel disease
Authors
Khaled Greish
Safa Taha
Anfal Jasim
Sara Abd Elghany
Ameera Sultan
Ali AlKhateeb
Manal Othman
Fang Jun
Sebastien Taurin
Moiz Bakhiet
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Clinical and Translational Medicine / Issue 1/2017
Electronic ISSN: 2001-1326
DOI
https://doi.org/10.1186/s40169-017-0157-2

Other articles of this Issue 1/2017

Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast cancer patients

  • Open Access
  • Research

Proteomics in asthma: the clinicians were right after all, were not they?

  • Open Access
  • Commentary

Biofluid lipidome: a source for potential diagnostic biomarkers

  • Open Access
  • Review

MRI detection of endothelial cell inflammation using targeted superparamagnetic particles of iron oxide (SPIO)

  • Open Access
  • Research

Significance of long chain polyunsaturated fatty acids in human health

  • Open Access
  • Review

A systematic approach to cancer: evolution beyond selection

  • Open Access
  • Perspective